We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.05B
1-Year Est. Return 125.28%
This Fund
S&P 500
This Quarter Est. Return
+2.21%
1 Year Est. Return
+125.28%
3 Year Est. Return
+334.72%
5 Year Est. Return
+344.07%
10 Year Est. Return
+2,748.76%
AUM
$5.06B
AUM Growth
-$395M
Cap. Flow
-$256M
Cap. Flow %
-5.05%
Top 10 Hldgs %
43.96%
Holding
127
New
13
Increased
22
Reduced
22
Closed
13

Top Buys

Rank Stock Value
1
ITGR icon
Integer Holdings
ITGR
+$40.8M
2
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$39.5M
3
EXAS
Exact Sciences
EXAS
+$29.3M
4
ARGX icon
argenx
ARGX
+$22M
5
AMGN icon
Amgen
AMGN
+$21M

Top Sells

Rank Stock Value
1
ALPN
Alpine Immune Sciences Inc
ALPN
+$106M
2
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$104M
3
JANX icon
Janux Therapeutics
JANX
+$60.8M
4
ESPR
Esperion Therapeutics
ESPR
+$36.7M
5
SRRK icon
Scholar Rock
SRRK
+$30.6M

Sector Composition

Rank Sector Weight
1 Healthcare 98.69%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
KROS icon
26
Keros Therapeutics
KROS
$196M
$58M 1.14%
1,268,734
– –
CRNX icon
27
Crinetics Pharmaceuticals
CRNX
$8.88B
$57.4M 1.13%
1,280,800
-104,200
-8% -$4.81M
UNH icon
28
UnitedHealth
UNH
$387B
$57M 1.13%
112,000
+42,000
+60% +$20.6M
AVBP icon
29
ArriVent BioPharma
AVBP
$1.36B
$56.2M 1.11%
3,027,328
– –
ICLR icon
30
Icon
ICLR
$13.7B
$54.6M 1.08%
174,100
– –
TERN
31
DELISTED
Terns Pharmaceuticals
TERN
$51.9M 1.02%
7,619,135
– –
APLS
32
DELISTED
Apellis Pharmaceuticals
APLS
$50M 0.99%
1,302,800
+5,000
+0.4% +$226K
EVH icon
33
Evolent Health
EVH
$391M
$49.8M 0.98%
2,605,615
– –
XTNT icon
34
Xtant Medical Holdings
XTNT
$59.1M
$46.1M 0.91%
73,114,592
– –
CYTK icon
35
Cytokinetics
CYTK
$10.6B
$44M 0.87%
812,906
+130,206
+19% +$7.86M
AMGN icon
36
Amgen
AMGN
$211B
$42.1M 0.83%
134,900
+71,500
+113% +$21M
SIBN icon
37
SI-BONE Inc
SIBN
$809M
$41.8M 0.82%
3,229,977
+55,456
+2% +$792K
PRLD icon
38
Prelude Therapeutics
PRLD
$364M
$41.6M 0.82%
10,909,256
– –
VRNA
39
DELISTED
Verona Pharma
VRNA
$41.4M 0.82%
2,861,801
-536,266
-16% -$7.83M
QTTB icon
40
Q32 Bio
QTTB
$448M
$40.4M 0.8%
2,252,987
– –
ITGR icon
41
Integer Holdings
ITGR
$3.42B
$40.4M 0.8%
+349,221
New +$40.8M
SNDX icon
42
Syndax Pharmaceuticals
SNDX
$1.68B
$39.5M 0.78%
1,925,300
+176,300
+10% +$3.69M
GERN icon
43
Geron
GERN
$911M
$37.9M 0.75%
8,930,252
-3,963,359
-31% -$15.5M
XENE icon
44
Xenon Pharmaceuticals
XENE
$6.17B
$33.6M 0.66%
862,362
+312,362
+57% +$12.5M
DXCM icon
45
DexCom
DXCM
$29.3B
$32.9M 0.65%
289,900
+149,600
+107% +$18.9M
RYTM icon
46
Rhythm Pharmaceuticals
RYTM
$7.35B
$28.9M 0.57%
704,842
– –
RNAM
47
DELISTED
Avidity Biosciences
RNAM
$28.9M 0.57%
706,475
-287,625
-29% -$8.25M
EXAS
48
DELISTED
Exact Sciences
EXAS
$28.4M 0.56%
672,416
+532,016
+379% +$29.3M
NPCE icon
49
Neuropace
NPCE
$483M
$25.8M 0.51%
3,406,335
-597,632
-15% -$6.03M
DYN icon
50
Dyne Therapeutics
DYN
$4.1B
$25M 0.49%
708,400
– –
1
2
3 4 5

Similar funds

HSA
HBK Sorce Advisory Erie, Pennsylvania $5.05B AUM 16.64% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.02B AUM 7.87% 1-Year Est. Return
BPWM
Badgley Phelps Wealth Managers Seattle, Washington $5.02B AUM 21.87% 1-Year Est. Return
LFG
Lazard Frères Gestion Paris, France $5.07B AUM 20.66% 1-Year Est. Return
JIM
Jensen Investment Management Lake Oswego, Oregon $5.07B AUM 4.98% 1-Year Est. Return
CTC
Central Trust Company Jefferson City, Missouri $5.08B AUM 25.65% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return
SGM
Skye Global Management West Palm Beach, Florida $5B AUM 11.9% 1-Year Est. Return

OrbiMed's Q2 2024 Portfolio in Review

As of Q2 2024, OrbiMed held 127 positions worth $5.06B, down 7.2% from $5.46B the previous quarter. Its ten largest holdings account for 44% of the portfolio.

OrbiMed withdrew a net $256M in Q2 2024, closing 13 positions and reducing 22 holdings. Its most notable exit was Alpine Immune Sciences Inc, an estimated $106M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 99% a quarter earlier.

Against the trend, OrbiMed opened a new position in Integer Holdings worth $40.4M.

  • OrbiMed's largest Q2 2024 buy was Integer Holdings: 349,221 shares worth $40.4M.
  • OrbiMed added most to Exact Sciences in Q2 2024, an estimated $29.3M increase.
  • OrbiMed's biggest Q2 2024 reduction was BioMarin Pharmaceuticals, cutting an estimated $104M.
  • OrbiMed fully exited Alpine Immune Sciences Inc in Q2 2024, selling an estimated $106M.
  • OrbiMed's ten largest holdings make up 44% of its $5.06B portfolio in Q2 2024.
  • OrbiMed opened 13 new positions and closed 13 in Q2 2024.
  • OrbiMed's portfolio value fell 7.2% quarter-over-quarter to $5.06B.

Based on OrbiMed's 13F filing for Q2 2024, filed 14 Aug 2024.